Company Profile
Immunome Stock Price, News & Analysis
- Ticker:
- IMNM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
26.25 USD (+2.18%)
Close
Last updated: August 11, 2026
2.19B USD
Market cap
Why the stock is moving
As of Aug 11, 2026, IMNM closed up 2.18% at $26.25. No new same-company headline was identified in the current news window.
Company overview
Business overview
Immunome is a biotechnology company focused on antibody discovery and oncology, with a platform that seeks to translate immune recognition into therapeutic programs. Its story is about building value from discovery engines and targeted cancer biology.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Immunome sits in specialty biotechnology.
Business Model Characteristics
The company depends on platform validation, clinical progress, and the ability to create differentiated oncology assets.
Position Within the Biotechnology Landscape
Immunome is a platform oncology name whose valuation is sensitive to translational and strategic progress.
Future catalysts
- Immunome’s catalysts are its antibody-discovery platform and oncology pipeline, especially any update that shows the company can still produce differentiated assets. The next readout matters because the platform still needs to prove itself.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immunome (IMNM)?
Immunome (IMNM) most recently closed at 26.25 USD, a +2.18% move versus the previous session.
What is the market cap of Immunome (IMNM)?
Immunome currently has a market capitalization of 2.19B USD on BioPharmSignal.
What does Immunome do?
Immunome is a biotechnology company focused on antibody discovery and oncology, with a platform that seeks to translate immune recognition into therapeutic programs. Its story is about building value from discovery engines and targeted cancer biology.
On which exchange is IMNM stock listed?
Immunome (IMNM) is associated with NASDAQ, United States, Biopharma.
What is Immunome?
Immunome’s catalysts are its antibody-discovery platform and oncology pipeline, especially any update that shows the company can still produce differentiated assets.
Which conditions is Immunome targeting with Immunome?
Immunome is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immunome describe recent progress with Immunome?
Immunome’s catalysts are its antibody-discovery platform and oncology pipeline, especially any update that shows the company can still produce differentiated assets.
What future catalysts are investors watching for Immunome?
Immunome’s catalysts are its antibody-discovery platform and oncology pipeline, especially any update that shows the company can still produce differentiated assets. The next readout matters because the platform still needs to prove itself.